Vytrus Biotech S.A (VYT) | Stock Overview & Key Data
Vytrus Biotech S.A Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: €20.60 on April 14, 2026
Explore how other Spanish stocks compare to their 52-week ranges: View ES Market 52-Week Insights
Key Statistics
Financial Highlights
Annual Income Flow
2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 144.69M Small-cap | 11.05% | 29.80% | 115.38% | 206.25% | 134.73% | 512.50% | 497.56% | 595.04% | 595.04% | 595.04% | 595.04% | |
|
Pharma Mar S.A
PHM
|
1.68B Large-cap | -2.77% | 9.23% | 17.43% | 27.39% | 23.89% | 30.10% | 151.19% | -0.37% | 186.82% | 180.20% | 30.59% |
| 220.00M Mid-cap | -3.13% | 0.72% | -12.81% | -12.81% | -13.35% | 2.95% | 31.60% | -21.41% | -5.42% | -21.41% | -21.41% | |
| 19.30M Small-cap | 8.33% | 13.04% | 30.00% | -27.78% | 30.00% | -16.13% | -21.21% | -70.79% | -91.88% | -88.50% | -88.50% | |
|
Atrys Health S.A
ATRY
|
222.81M Mid-cap | -3.65% | 7.41% | -3.65% | -14.20% | -0.68% | 1.75% | -42.91% | -69.15% | 81.25% | 81.25% | 81.25% |
|
Grifols, S.A
GRF
|
6.09B Large-cap | -7.25% | 1.24% | -18.49% | -20.87% | -20.02% | 5.17% | -3.97% | -60.31% | -52.89% | 33.98% | 244.23% |
Ownership & Short Interest
Calculate Your Vytrus Biotech S.A Investment Returns
Long-Term Investment Performance Analysis
Vytrus Biotech S.A stock price in Mar 2022 was €2.82, A €1,000.00 lump sum investment in Vytrus Biotech S.A made 4 years ago would be worth approximately €6,950.35 today, representing a exceptional return of 595.04%. This translates to an annualized return (CAGR) of 60.23%.
4 Years 1 Month Investment Scenario (Mar 2022 - Apr 2026)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is VYT's 52-week high and low?
- In the last 52 weeks, Vytrus Biotech S.A reached a high of €20.60 (on April 14, 2026) and a low of €3.04 (on May 20, 2025).
- What is the market cap and P/E ratio for VYT?
- Curious about Vytrus Biotech S.A's size and valuation? Its market capitalization stands at 144.69M. When it comes to valuation, the P/E ratio (trailing twelve months) is 49.36, and the forward P/E (looking ahead) is 32.43.
- Does VYT pay dividends? If so, what's the yield?
- As for dividends, Vytrus Biotech S.A isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Vytrus Biotech S.A's main competitors or similar companies to consider before investing?
When looking at Vytrus Biotech S.A, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Pharma Mar S.A
PHM1.68B Healthcare Biotechnology 30.10% 151.19% Oryzon Genomics S.A
ORY220.00M Healthcare Biotechnology 2.95% 31.60% Biotechnology Assets
BST19.30M Healthcare Biotechnology -16.13% -21.21% Atrys Health S.A
ATRY222.81M Healthcare Biotechnology 1.75% -42.91% Grifols, S.A
GRF6.09B Healthcare Drug Manufacturers - General 5.17% -3.97% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Vytrus Biotech S.A.? (e.g., ROE, Debt/Equity)
- To get a sense of Vytrus Biotech S.A's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 32.92%, the Debt to Equity ratio from the most recent quarter is 12.03, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for VYT?
- Looking at Vytrus Biotech S.A's growth, its revenue over the trailing twelve months (TTM) was €10M. Compared to the same quarter last year (YoY), quarterly revenue grew by 52.60%, and quarterly earnings saw a YoY growth of 185.10%.
- How much of VYT stock is held by insiders and institutions?
- Wondering who owns Vytrus Biotech S.A stock? Company insiders (like executives and directors) hold about 64.89% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 0.35%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.